disulfiram has been researched along with imatinib mesylate in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Al-Tamimi, J; Alhazza, IM; Aman, S; Ebaid, H; Hassan, I; Khan, AA; Qamar, W; Rady, AM | 1 |
| Abdel-Mageed, AM; Al-Tamimi, J; Alhazza, IM; Aman, S; Ebaid, H; Hassan, I | 1 |
3 other study(ies) available for disulfiram and imatinib mesylate
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Restrained management of copper level enhances the antineoplastic activity of imatinib in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Survival; Chemotherapy, Adjuvant; Copper; Disulfiram; Drug Synergism; Imatinib Mesylate; Metabolism; Neoplasms, Experimental; Rats; Treatment Outcome | 2018 |
Copper Mediates Anti-Inflammatory and Antifibrotic Activity of Gleevec in Hepatocellular Carcinoma-Induced Male Rats.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Chelating Agents; Copper; Cytokines; Disulfiram; Imatinib Mesylate; Inflammation; Inflammation Mediators; Liver Neoplasms; Male; Rats; Rats, Wistar | 2019 |